Low 25(OH)Vitamin D levels are associated with nutritional risk and disease severity in outpatient individuals with advanced chronic liver disease Authors: Josile Maria da Conceição Albuquerque, José Israel Rodrigues Junior, Aryana Isabelle de Almeida Neves Siqueira, Juliana Célia de Farias Santos, João Araújo de Barros-Neto, Nassib Bezerra Bueno, Fabiana Andréa Moura Published: 2026 ABSTRACT Content of image described in text. Introduction Active vitamin D [1,25(OH)2VitD] serves a variety of functions in the body including modulating of the immune system, cell differentiation and proliferation, and inflammatory processes.(1) To become biologically active, VitD undergoes two sequential hydroxylation reactions: the first occurs in the liver, forming 25(OH)VitD (most abundant in circulation),(2) and the second takes place in the kidneys, where it is converted into the active form, 1,25(OH)2VitD.(3) Since its metabolism occurs in the liver, low 25(OH)VitD levels are commonly observed in patients with advanced chronic liver disease (ACLD).(4,5) This is particularly concerning given that 25(OH)VitD has a supposed suppressive effect on collagen production in hepatic stellate cells, which may regulate the fibrotic process.(3,6) The close association between low 25(OH)VitD levels, malnutrition, and sarcopenia is widely recognised in children, adults, and the elderly, as these conditions can develop from various factors and occur successively or simultaneously. Impaired macronutrient and micronutrient intake and absorption, combined with increased gluconeogenesis from amino acids, favours muscle depletion and elevates the risk of sarcopenia.(7,8) Although the mechanisms by which 25(OH)VitD acts on muscle are not fully clear, there is evidence that its receptor, the vitamin D receptor (VDR), induces cell differentiation and proliferation. It does this by positively regulating growth factors such as Insulin-like Growth Factor-1 (IGF-1) and follistatin, while also inhibiting the expression of myostatin, a key regulator of muscle growth.(5) The strong connection between low 25(OH)VitD levels and sarcopenia has been consistently investigated in recent years. For instance, patients with decompensated cirrhosis (Child-Pugh B and C) and sarcopenia, or very low levels of this vitamin (<10 ng/mL), had a worse clinical prognosis.(9) Other studies also observed that 25(OH)VitD levels <25 ng/mL were independently associated with sarcopenia in individuals with ACLD.(10) However, despite these results, there is a lack of uniformity among authors regarding the diagnosis of sarcopenia in individuals with ACLD. In some cases, the method for identifying muscle mass is not described, or the authors use techniques that are not appropriate for this population, such as bioimpedance. To address this methodological inconsistency and ensure diagnostic rigour, our study utilised Dual-Energy X-ray Absorptiometry (DXA), a recommended method for assessing skeletal muscle mass in this patient population. Therefore, this study aimed to evaluate the association between serum 25(OH)VitD levels and disease severity in individuals with ACLD. Furthermore, we investigated the relationship between 25(OH)VitD and nutritional and functional status, specifically focusing on nutritional risk, sarcopenia, and physical frailty. Materials and methods Study design and setting This is a cross-sectional study derived from a larger research project conducted at the Infectious and Parasitic Diseases Department of Professor Alberto Antunes University Hospital, Maceió, Alagoas, Brazil. Data were collected from October 2022 to November 2023. The study design and reporting followed the guidelines of the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE). Sample and study groups The study included patients aged 18 to 70 years, of both sexes, diagnosed with ACLD and portal hypertension. Portal hypertension was defined by the presence of ascites, splenomegaly, esophagogastric varices, or portosystemic collaterals (patent paraumbilical vein, splenorenal collaterals, dilated left gastric veins, and short veins). Exclusion criteria were (a) neoplasia; (b) acute liver failure; (c) pregnant and lactating women; (d) human immunodeficiency virus infection; (e) patients listed for liver transplantation due to special conditions (intractable pruritus, recurrent cholangitis, refractory ascites, persistent hepatic encephalopathy); and (f) history of organ failure affecting nutritional status, such as renal replacement therapy, respiratory, and cardiac failure. Sample size calculation This was an exploratory study derived from a project that originally aimed to identify the prevalence of sarcopenia among liver transplant (LT) candidates (MELD-Na ≥ 15). A relative risk of 3 for sarcopenia prevalence was expected, with a baseline prevalence of 25% in the control group (patients with ACLD but without LT indication). Assuming 80% power and a 5% alpha level, 19 patients were required in each group (MELD-Na ≤ 14 and MELD-Na ≥ 15). The final sample of 47 patients exceeded the minimum requirement, ensuring adequate power for the primary objectives of the parent study. Data collection and assessments Liver disease severity assessment The severity of liver disease was assessed using the MELD-Na (≤14 and ≥15), MELD 3.0 (≤10 and ≥11), and Child-Pugh scores (A and B/C). All scores were determined by a specialised medical professional based on clinical evaluation and laboratory test results obtained at the time of consultation. Sociodemographic and clinical data Sociodemographic and clinical data, including personal and current disease history, presence of signs and symptoms, lifestyle habits, disease aetiology, and time of diagnosis, were collected using a standardised form. Nutritional and functional assessment To ensure a rigorous nutritional and functional assessment appropriate for this patient population, we used tools and techniques specifically validated for individuals with advanced chronic liver disease. Nutritional risk was assessed using the Royal Free Hospital Nutritional Prioritising Tool (RFH-NPT). Patients were classified as having nutritional risk if their RFH-NPT score was ≥1 point. Nutritional status was identified using the Royal Free Hospital Global Assessment (RFH-GA) and classified as malnourished based on the tool’s flowchart. Arm circumference (AC) and triceps skinfold (TSF) were measured and used to calculate RFH-GA. Body Mass Index (BMI) was calculated using the patients’ current weight. For those with ascites or oedema, an estimated weight was obtained by subtracting a percentage of weight based on the severity of ascites (5% for mild, 10% for moderate, and 15% for severe)(8) or by reducing 1, 3, or 6 kg for mild, moderate, or severe lower limb oedema, respectively.(11) The nutritional status categories were underweight, adequate weight, overweight, and obesity, based on specific cutoffs for adults and older adults.(12,13) BMI was also used for the RFH-GA tool. Skeletal muscle mass was evaluated by DXA, performed with the patient in a supine position with legs extended, feet together, and arms at their side. Upper and lower limb muscle mass were summed to determine Appendicular Skeletal Muscle Mass (ASMM), and its index (ASMMI) was calculated as ASMM/height2. Muscle mass reduction was defined as ASMM < 20 kg or ASMMI < 7 kg/m2 for men, and ASMM < 15 kg or ASMMI < 5.5 kg/m2 for women.(14) Muscle strength and functional capacity were assessed using handgrip strength (HGS) and the five-times sit-to-stand test. HGS was measured three times on the dominant hand, with the average used to classify decreased muscle strength (<27 kgf for men and <16 kgf for women), according to Brazilian studies.(15,16) Low muscle strength in the sit-to-stand test was defined as a time exceeding 15 s for five repetitions.(14) Sarcopenia was diagnosed when both low muscle strength (HGS or sit-to-stand test) and reduced muscle mass (ASMM or ASMMI) were present.(17) Physical frailty was assessed using the Liver Frailty Index (LFI), calculated from handgrip strength, the five-times sit-to-stand test, and a standardised balance test. Scores were determined using the official University of California, San Francisco (UCSF) calculator (https://liverfrailtyindex.ucsf.edu/). For statistical purposes, patients were categorised as ‘Robust’ (LFI <3.2) or ‘Frail’ (≥3.2, including pre-frail and frail individuals). 25(OH)VitD level assessment Serum 25(OH)VitD levels were assessed on the day of consultation using a chemiluminescence method on fasting samples. Vitamin insufficiency was defined as serum 25(OH)VitD levels <30 ng/mL. Equipment and techniques Body weight and height were measured using a Filizola® digital scale and a metal anthropometer. AC was measured with a non-extensible tape, while TSF was assessed with a Lange® calliper. ASMM was obtained via DXA analysis using a Lunar Prodigy Primo system (GE HealthCare). HGS was measured using a Jamar® dynamometer. All measurements were performed by trained professionals. Efforts to address potential sources of bias Selection bias To minimise selection bias, clear eligibility criteria were applied to ensure only patients meeting predefined conditions were included. The sample was drawn from a single university hospital, and all eligible adult patients during the study period were invited to participate, avoiding selective inclusion. Efforts were also made to ensure a representative sample, including patients of both sexes and with diverse aetiologies of liver disease. Measurement bias To reduce measurement bias, standardised protocols were used for all anthropometric and functional assessments. Body composition was measured using DXA, HGS, and the sit-to-stand test. Nutritional parameters were evaluated by trained professionals using calibrated equipment. The same tools and methods were consistently applied to all patients. Confounding factors Potential confounding factors, such as age, sex, and aetiology of liver cirrhosis, were controlled for in the multivariate regression analysis. Ethical considerations All patients provided written informed consent. The study was conducted in accordance with the ethical guidelines of the 1975 Helsinki Declaration. The protocol was approved by the Ethics Committee on May 26, 2022 (Opinion Number 5432777). Statistical analysis All analyses were conducted using SPSS® version 26.0 (Chicago, IL, USA). Results were expressed as absolute and relative frequencies (n/%) or as means and standard deviations. Chi-square or Fisher’s exact tests were applied as appropriate. Logistic regression analyses were performed with 25(OH)VitD insufficiency as the dependent variable. Two adjusted models were constructed: Model 1 included clinical and nutritional variables (Child-Pugh, MELD-Na, Ascites, RFH-NPT, RFH-GA, and frailty) adjusted for sex, age, and aetiology. Model 2 included MELD 3.0 and sarcopenia, adjusted only for age and aetiology, as sex is already incorporated into the MELD 3.0 formula. A significance level of 5% was adopted. Results A total of 47 individuals were evaluated, of whom 76.6% (n = 36) had insufficient 25(OH)VitD levels. Two patients were receiving vitamin D supplementation; however, both showed reduced 25(OH)D levels and were therefore included in the analysis. Of the participants included in the study, 72.3% were male, with a mean age of 48 ± 14.2 years. No statistically significant differences were observed between individuals with adequate or insufficient 25(OH)VitD levels regarding sociodemographic characteristics. Regarding disease aetiology, alcoholic origin was the most prevalent (48.9%), followed by cryptogenic (14.9%), autoimmune (12.8%), and Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD, 6.4%). Regarding clinical status, the prevalence of 25(OH)VitD insufficiency was significantly higher among individuals with more severe disease. Specifically, 72.2% of patients with Child-Pugh B or C scores had vitamin insufficiency, compared to 27.8% in the Child-Pugh A group (p = 0.012). Additionally, the presence of ascites was significantly associated with insufficiency (58.3% vs. 41.7%; p = 0.010), reinforcing the link between low vitamin D levels and clinical decompensation (Table 1). Table 1.Sociodemographic characteristics of patients with advanced chronic liver disease, according to the presence of insufficient 25(OH)VitD levels Table 1 long description. Variable25(OH)VitD levels p-ValueTotal Insufficiency (<30 ng/mL) Adequate (≥30 ng/mL) n (%) n (%) n (%)Self-declared race0.226 White12 (25.5)7 (19.4)5 (45.5) Non-White35 (74.5)29 (80.6)6 (54.5)Education0.081 >Elementary school26 (55.3)17 (47.2)9 (81.8) Elementary school26 (55.3)17 (47.2)9 (81.8)